Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 4Head & Neck 2Breast 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 2573Uterine Cervical Neoplasms 1693Endometrial Neoplasms 1012Fallopian Tube Neoplasms 730Carcinoma, Ovarian Epithelial 681Breast Neoplasms 676Neoplasms 436Carcinoma, Non-Small-Cell Lung 379Colorectal Neoplasms 372Stomach Neoplasms 302Pancreatic Neoplasms 302Uterine Cervical Dysplasia 273Prostatic Neoplasms 262Lung Neoplasms 250Melanoma 247Neoplasm Metastasis 216Peritoneal Neoplasms 197Carcinoma, Renal Cell 193Sarcoma 190Head and Neck Neoplasms 189Urinary Bladder Neoplasms 187Esophageal Neoplasms 187Recurrence 185Triple Negative Breast Neoplasms 181Uterine Neoplasms 176Vulvar Neoplasms 173Squamous Cell Carcinoma of Head and Neck 168Colonic Neoplasms 162Papillomavirus Infections 153Small Cell Lung Carcinoma 128

Interventions

pembrolizumab 1E7046 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Spinocerebellar Degenerations × Gynecologic × Clear all
NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡